| Eric John Chapman, DO | |
|
2024 S 6th St, Brainerd, MN 56401-4529 | |
| (218) 828-7100 | |
| Not Available |
| Full Name | Eric John Chapman |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 14 Years |
| Location | 2024 S 6th St, Brainerd, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003136839 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 59670 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Essentia Health St Joseph's Medical Center | Brainerd, MN | Hospital |
| Tri County Hospital | Wadena, MN | Hospital |
| Essentia Health | Fargo, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Astera Health | 2961395272 | 94 |
| St Josephs Medical Center | 8224948443 | 215 |
News Archive
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.
An individualized and family-based physical activity and dietary intervention reduced the plasma LDL cholesterol concentration of primary school children, a new study from the University of Eastern Finland shows.
Now, a new study addresses the possible use of an FDA-approved monoclonal antibody, called fostamatinib, a spleen tyrosine kinase inhibitor (SYK), to reduce the levels of mucin-1, a molecule associated with acute lung injury and acute respiratory distress syndrome (ARDS). People who have severe COVID-19 disease may develop ARDS.
Second hand smoke exposure is associated with psychological distress and risk of future psychiatric illness, according to new UCL research that suggests the harmful affects of passive smoking go beyond physical health.
The Center for Healthy Minds at the University of Wisconsin-Madison and the Madison Police Department are launching a pilot study to better understand the impact of mindfulness-based practices on police officers' physical and mental well-being.
› Verified 5 days ago
| Entity Name | St Josephs Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568415974 PECOS PAC ID: 8224948443 Enrollment ID: O20031119000468 |
News Archive
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.
An individualized and family-based physical activity and dietary intervention reduced the plasma LDL cholesterol concentration of primary school children, a new study from the University of Eastern Finland shows.
Now, a new study addresses the possible use of an FDA-approved monoclonal antibody, called fostamatinib, a spleen tyrosine kinase inhibitor (SYK), to reduce the levels of mucin-1, a molecule associated with acute lung injury and acute respiratory distress syndrome (ARDS). People who have severe COVID-19 disease may develop ARDS.
Second hand smoke exposure is associated with psychological distress and risk of future psychiatric illness, according to new UCL research that suggests the harmful affects of passive smoking go beyond physical health.
The Center for Healthy Minds at the University of Wisconsin-Madison and the Madison Police Department are launching a pilot study to better understand the impact of mindfulness-based practices on police officers' physical and mental well-being.
› Verified 5 days ago
| Entity Name | Astera Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134305162 PECOS PAC ID: 2961395272 Enrollment ID: O20040202001082 |
News Archive
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.
An individualized and family-based physical activity and dietary intervention reduced the plasma LDL cholesterol concentration of primary school children, a new study from the University of Eastern Finland shows.
Now, a new study addresses the possible use of an FDA-approved monoclonal antibody, called fostamatinib, a spleen tyrosine kinase inhibitor (SYK), to reduce the levels of mucin-1, a molecule associated with acute lung injury and acute respiratory distress syndrome (ARDS). People who have severe COVID-19 disease may develop ARDS.
Second hand smoke exposure is associated with psychological distress and risk of future psychiatric illness, according to new UCL research that suggests the harmful affects of passive smoking go beyond physical health.
The Center for Healthy Minds at the University of Wisconsin-Madison and the Madison Police Department are launching a pilot study to better understand the impact of mindfulness-based practices on police officers' physical and mental well-being.
› Verified 5 days ago
| Entity Name | Astera Health |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1477545333 PECOS PAC ID: 2961395272 Enrollment ID: O20060504000722 |
News Archive
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.
An individualized and family-based physical activity and dietary intervention reduced the plasma LDL cholesterol concentration of primary school children, a new study from the University of Eastern Finland shows.
Now, a new study addresses the possible use of an FDA-approved monoclonal antibody, called fostamatinib, a spleen tyrosine kinase inhibitor (SYK), to reduce the levels of mucin-1, a molecule associated with acute lung injury and acute respiratory distress syndrome (ARDS). People who have severe COVID-19 disease may develop ARDS.
Second hand smoke exposure is associated with psychological distress and risk of future psychiatric illness, according to new UCL research that suggests the harmful affects of passive smoking go beyond physical health.
The Center for Healthy Minds at the University of Wisconsin-Madison and the Madison Police Department are launching a pilot study to better understand the impact of mindfulness-based practices on police officers' physical and mental well-being.
› Verified 5 days ago
| Entity Name | Brainerd Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295801777 PECOS PAC ID: 0648270272 Enrollment ID: O20070105000140 |
News Archive
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.
An individualized and family-based physical activity and dietary intervention reduced the plasma LDL cholesterol concentration of primary school children, a new study from the University of Eastern Finland shows.
Now, a new study addresses the possible use of an FDA-approved monoclonal antibody, called fostamatinib, a spleen tyrosine kinase inhibitor (SYK), to reduce the levels of mucin-1, a molecule associated with acute lung injury and acute respiratory distress syndrome (ARDS). People who have severe COVID-19 disease may develop ARDS.
Second hand smoke exposure is associated with psychological distress and risk of future psychiatric illness, according to new UCL research that suggests the harmful affects of passive smoking go beyond physical health.
The Center for Healthy Minds at the University of Wisconsin-Madison and the Madison Police Department are launching a pilot study to better understand the impact of mindfulness-based practices on police officers' physical and mental well-being.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Eric John Chapman, DO 523 N 3rd St, Brainerd, MN 56401-3054 Ph: (218) 829-2861 | Eric John Chapman, DO 2024 S 6th St, Brainerd, MN 56401-4529 Ph: (218) 828-7100 |
News Archive
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.
An individualized and family-based physical activity and dietary intervention reduced the plasma LDL cholesterol concentration of primary school children, a new study from the University of Eastern Finland shows.
Now, a new study addresses the possible use of an FDA-approved monoclonal antibody, called fostamatinib, a spleen tyrosine kinase inhibitor (SYK), to reduce the levels of mucin-1, a molecule associated with acute lung injury and acute respiratory distress syndrome (ARDS). People who have severe COVID-19 disease may develop ARDS.
Second hand smoke exposure is associated with psychological distress and risk of future psychiatric illness, according to new UCL research that suggests the harmful affects of passive smoking go beyond physical health.
The Center for Healthy Minds at the University of Wisconsin-Madison and the Madison Police Department are launching a pilot study to better understand the impact of mindfulness-based practices on police officers' physical and mental well-being.
› Verified 5 days ago
Dr. Scott Charles Wheeler, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2024 S 6th St, Brainerd, MN 56401 Phone: 218-828-7100 Fax: 218-833-8037 | |
Mr. Bradley James Qualey, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2024 S 6th St, Ste 3, Brainerd, MN 56401 Phone: 218-828-7100 Fax: 218-833-8037 | |
Mr. David Brian Paul, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 15620 Edgewood Dr, Ste 200, Brainerd, MN 56401 Phone: 218-330-6999 Fax: 218-825-8027 | |
Gates C Cook, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 2024 S 6th St, Brainerd, MN 56401 Phone: 218-828-7101 |